The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas

Histology and Histopathology

Volumn 25, Issue 11, 2010, Pages 1447-1456

  Brüning, Ansgar ^a   Jückstock, Julia ^a   Blankenstein, Thomas ^a   Makovitzky, Josef ^b   Kunze, Susanne ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endometrioid adenocarcinomas; ER alpha; ER beta; Estrogen receptors; Immunohistochemistry; MTA3; Prognosis; Survival

Indexed keywords

ESTROGEN RECEPTOR; MTA3 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; DISEASE FREE SURVIVAL; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79551587199     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Abeler V.M. and Kjorstad K.E. (1991). Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 67, 3093-3103.
2. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E. and Vergote I. (2005). Endometrial cancer. Lancet 366, 491-505.
3. Auerkari E.I. (2006). Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol. 42, 5-13.
4. Balasenthil S., Broaddus R.R. and Kumar R. (2006). Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum. Pathol. 37, 656-661.
5. Beavon I.R. (2000). The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur. J. Cancer 36, 1607-1620.
6. Blechschmidt K., Kremmer E., Hollweck R., Mylonas I., Hofler H., Kremer M. and Becker K.F. (2007). The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn. Mol. Pathol. 16, 222-228.
7. Blechschmidt K., Sassen S., Schmalfeldt B., Schuster T., Hofler H. and Becker K.F. (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br. J. Cancer 98, 489-495.
8. Brüning A., Makovitzky J., Gingelmaier A., Friese K. and Mylonas I. (2009). The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem. Cell Biol. 132, 33-38.
9. Castro Alves C., Rosivatz E., Schott C., Hollweck R., Becker I., Sarbia M., Carneiro F. and Becker K.F. (2007). Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J. Pathol. 211, 507-515.
10. Chan J.K., Wu H., Cheung M.K., Shin J.Y., Osann K. and Kapp D.S. (2007). The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol. Oncol. 106, 282-288.
11. Cox D.R. (1972). Regression models and life tables. J. R. Stat. Soc. B. 34, 187-220.
12. Dannenmann C., Shabani N., Friese K., Jeschke U., Mylonas I. and Brüning A. (2008). The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol. Ther. 7, 1460-1467.
13. Deroo B.J. and Korach K.S. (2006). Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570.
14. FIGO (1989). FIGO stages (announcements). Gynecol. Oncol. 35, 125-127.
15. Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S. and Wade P.A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113, 207-219.
16. Giacinti L., Claudio P.P., Lopez M. and Giordano A. (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11, 1-8.
17. Gloeckler Ries L.A., Reichman M.E., Lewis D.R., Hankey B.F. and Edwards B.K. (2003). Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541-552.
18. Hanahan D. and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
19. Herynk M.H. and Fuqua S.A. (2004). Estrogen receptor mutations in human disease. Endocr. Rev. 25, 869-898.
20. Hugo H., Ackland M.L., Blick T., Lawrence M.G., Clements J.A., Williams E.D. and Thompson E.W. (2007). Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J. Cell Physiol. 213, 374-383.
21. Jeon Y.T., Park I.A., Kim Y.B., Kim J.W., Park N.H., Kang S.B., Lee H.P. and Song Y.S. (2006). Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 239, 198-204.
22. Jereczek-Fossa B., Badzio A. and Jassem J. (1999). Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int. J. Gynecol. Cancer 9, 285-294.
23. Jongen V., Briet J., de Jong R., ten Hoor K., Boezen M., van der Zee A., Nijman H. and Hollema H. (2009). Expression of estrogen receptoralpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol. Oncol. 112, 537-542.
24. Kaplan E.L. and Meier P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
25. Leader J.E., Wang C., Popov V.M., Fu M. and Pestell R.G. (2006). Epigenetics and the estrogen receptor. Ann. NY Acad. Sci. 1089, 73-87.
26. Manavathi B., Singh K. and Kumar R. (2007). MTA family of coregulators in nuclear receptor biology and pathology. Nucl. Recept. Signal. 5, e010.
27. Moustakas A. and Heldin C.H. (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98, 1512-1520.
28. Mylonas I., Speer R., Makovitzky J., Richter D.U., Briese V., Jeschke U. and Friese K. (2000). Immunohistochemical analysis of steroid receptors and glycodelin A (PP14) in isolated glandular epithelial cells of normal human endometrium. Histochem. Cell Biol. 114, 405-411.
29. Mylonas I., Jeschke U., Shabani N., Kuhn C., Balle A., Kriegel S., Kupka M.S. and Friese K. (2004). Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem. 106, 245-252.
30. Mylonas I., Jeschke U., Shabani N., Kuhn C., Kriegel S., Kupka M.S. and Friese K. (2005). Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res. 25, 1679-1686.
31. Mylonas I., Jeschke U., Shabani N., Kuhn C., Kunze S., Dian D., Friedl C., Kupka M.S. and Friese K. (2007). Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol. Histopathol. 22, 169-176.
32. Mylonas I., Worbs S., Shabani N., Kuhn C., Kunze S., Schulze S., Dian D., Gingelmaier A., Schindlbeck C., Bruning A., Sommer H., Jeschke U. and Friese K. (2009). Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur. J. Cancer 45, 1304-1314.
33. Oreskovic S., Babic D., Kalafatic D., Barisic D. and Beketic-Oreskovic L. (2004). A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol. Oncol. 93, 34-40.
34. Prat J. (2004). Prognostic parameters of endometrial carcinoma. Hum. Pathol. 35, 649-662.
35. Remmele W. and Schicketanz K.H. (1993). Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol. Res. Pract. 189, 862-866.
36. Rose P.G. (1996). Endometrial carcinoma. N. Engl. J. Med. 335, 640-649.
37. Shabani N., Kuhn C., Kunze S., Schulze S., Mayr D., Dian D., Gingelmaier A., Schindlbeck C., Willgeroth F., Sommer H., Jeschke U., Friese K. and Mylonas I. (2007a). Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur. J. Cancer 43, 2434-2444.
38. Shabani N., Mylonas I., Jeschke U., Thaqi A., Kuhn C., Puchner T. and Friese K. (2007b). Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res. 27, 2027-2033.
39. Sherman M.E. (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13, 295-308.
40. Vicovac L. and Aplin J.D. (1996). Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat. (Basel). 156, 202-216.
41. Yao Y.L. and Yang W.M. (2003). The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J. Biol. Chem. 278, 42560-42568.